Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab plus chemotherapy versus rituximab plus chemotherapy with maintenance in previously untreated advanced indolent non-Hodgkin lymphoma
2010-024132-41Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of obinutuzumab, rituximab and bendamustine in indolent lymphoma, follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL) (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival in patients with follicular lymphoma. Started Apr 2011; status: completed.
02
Drugs
obinutuzumabrituximabbendamustine
03
Conditions
indolent lymphomafollicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2010-024132-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024132-41.